Your session is about to expire
← Back to Search
Nimotuzumab for Non-Small Cell Lung Cancer
Study Summary
This trial is studying nimotuzumab given with nivolumab to see how well they work in treating patients with non-small cell lung cancer.
- Non-Small Cell Lung Cancer
- Epidermal Growth Factor Receptor Mutations
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to the ingredients in the study drugs or similar medicines.You have a heart problem that is not under control or you have trouble with your heart's function.You have a history of severe chest pain that cannot be controlled with medication.You are currently receiving any other cancer treatments besides nimotuzumab or nivolumab.You are expected to live for at least 3 more months.You have advanced lung cancer that has worsened after your first round of chemotherapy.You have a serious lung disease called interstitial lung disease (ILD).You currently have a serious infection that needs strong medication to treat it.You have been diagnosed with a heart condition called cardiomyopathy.You have brain metastases with symptoms, or uncontrolled fluid build-up around your lungs or heart.You have experienced severe heart inflammation or heart attack within the past year that did not get better with treatment.
- Group 1: Treatment (nivolumab, nimotuzumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Nimotuzumab an innocuous medication for individuals?
"Nimotuzumab has a score of 1 as it is still in Phase 1, indicating that there are only preliminary data attesting to its efficacy and safety."
How many participants are involved in the research project?
"Unfortunately, no new patients are currently being accepted into this trial; its last update was on September 27th 2022. If you're still interested in clinical trials for egfr gene mutations and Nimotuzumab there are presently 1920 and 737 studies recruiting respectively."
What medical purposes is Nimotuzumab commonly used for?
"Nimotuzumab is traditionally administered to combat metastatic ureter urothelial carcinoma, but it also has potential for treating malignant melanoma of skin, glioma and metastatic hepatocellular carcinoma."
Is there any evidence to suggest that Nimotuzumab has been utilized in previous clinical trials?
"Presently, there are 737 active medical studies involving Nimotuzumab. Of these trials, 88 have reached Phase 3 of the research process. These scientific investigations originate from Zürich, BE and span 40354 locations worldwide."
Are there any vacant slots available in this investigation?
"This clinical study is no longer recruiting patients. It was initially published on June 29th of 2017 and most recently updated on September 27th, 2022. Fortunately, there are many other trials looking for participants; 1920 studies related to EGFR gene mutations and 737 experiments regarding Nimotuzumab remain active."
Share this study with friends
Copy Link
Messenger